Documentation scienceplus.abes.fr version Bêta

À propos de : ▼Rivastigmine for Alzheimer's disease        

AttributsValeurs
type
Is Part Of
Subject
Title
  • ▼Rivastigmine for Alzheimer's disease
has manifestation of work
Abstract
  • ▼Rivastigmine (Exelon - Novartis) is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows ▼donepezil (Aricept - Eisai; Pfizer). Previously, we have been "unconvinced of the value of donepezil in routine clinical practice".1,2 Rivastigmine has been promoted with the slogan "Beyond cognition: improving functional ability". Does rivastigmine offer useful benefits in Alzheimer's disease?
article type
publisher identifier
  • dtdt0002
Alternative Title
  • ▼Rivastigmine for Alzheimer's disease
is part of this journal
PubMed ID
  • 10829350



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata